GlassScriptPhysician profile
Calvin J Reams
NPI 1427131101
$2,398.61
in general payments reported to CMS, 2019-2025
29 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.53 · 2021: $344 · 2022: $379 · 2023: $616 · 2024: $555 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $454.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $336.22 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $237.81 | 2022-2025 | |
| Glaxosmithkline, LLC. | $226.47 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $155.30 | 2021-2025 | |
| Almatica Pharma LLC | $113.24 | 2021-2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Corium, LLC | $102.03 | 2021-2023 | Azstarys |
| Astellas Pharma US INC | $75.19 | 2021-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $59.04 | 2025 | Zepbound, Mounjaro, Kisunla |
| Seqirus USA INC | $56.29 | 2022-2025 | Flucelvax, Fluad |
| Sanofi Pasteur INC. | $54.79 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.37 | 2022 | |
| Ironshore Pharmaceuticals INC. | $43.95 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.91 | 2021-2022 | |
| Exact Sciences Corporation | $38.37 | 2024-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $37.57 | 2023-2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $33.95 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $33.27 | 2023-2024 | Rexulti |
| Radius Health, INC. | $32.09 | 2024 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $29.32 | 2024-2025 | Airsupra, Farxiga |
| Hologic Sales and Service, LLC | $27.65 | 2023-2024 | Aptima |
| Genentech USA, INC. | $26.21 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $23.98 | 2022 | |
| Linus Health, INC. | $19.75 | 2023 | |
| Supernus Pharmaceuticals, INC. | $19.43 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.14 | 2021 | |
| Corcept Therapeutics | $18.97 | 2024 | Korlym |
| Abbott Laboratories | $18.58 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.69 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Reams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.